Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 969 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Group Regimen Clear all
Recruiting Phase 2Phase 3 Interventional

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

NCT07196722
View directory record Official record
Conditions
Crohn Disease
Interventions
Icotrokinra, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,092 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
61
States / cities
Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 1:29 AM EDT
Completed Phase 4 Interventional

Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes

NCT00191464
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
premeal insulin lispro mixtures, insulin glargine, metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
35 Years to 75 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 24, 2026, 1:29 AM EDT
Active, not recruiting Phase 2 Interventional

Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes

NCT04542148
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk, Diabetes, Gestational
Interventions
Sliding Scale Insulin, Up-Titration of Home Insulin, Continuous Insulin Infusion, Dexcom G6 Professional Continuous Glucose Monitor
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 50 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Portland, Oregon • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 24, 2026, 1:29 AM EDT
Completed Phase 2 Interventional

Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy

NCT00338767
View directory record Official record
Conditions
HIV Infections, Depression
Interventions
Directly Observed Therapy (DOT), Fluoxetine
Behavioral · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2013 · Synced Oct 24, 2026, 1:29 AM EDT
Terminated Phase 3 Interventional Results available

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

NCT04313881
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Magrolimab, Azacitidine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
47
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 24, 2026, 1:29 AM EDT
Terminated Phase 3 Interventional Results available

Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

NCT04258423
View directory record Official record
Conditions
Kidney Failure
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 24, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

NCT05923099
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
LEO 138559, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Fountain Valley, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 24, 2026, 1:29 AM EDT
Completed Early Phase 1 Interventional

Pain Control After Total Knee Arthroplasty: Benefit In Adding Single Shot Adductor Canal Block to Existing Pain Regimen Protocol?

NCT02740192
View directory record Official record
Conditions
Pain
Interventions
Adductor Canal Block, Periarticular Injection, Ropivacaine, Bupivacaine
Procedure · Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 24, 2026, 1:29 AM EDT
Completed Not applicable Interventional

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss

NCT04450602
View directory record Official record
Conditions
Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair, Hair Loss/Baldness, Hair Thinning
Interventions
ALRV5XR, ALRV5XR Shampoo, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment), Placebo, Placebo Shampoo, Placebo Conditioner, Placebo Hair Follicle Serum (Nutriment)
Dietary Supplement · Other
Lead sponsor
Arbor Life Labs
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 24, 2026, 1:29 AM EDT
Completed Not applicable Interventional Results available

Behavioral Economics to Improve Antihypertensive Therapy Adherence

NCT04029883
View directory record Official record
Conditions
Hypertension, Medication Adherence
Interventions
Text Message, Behavior Economic Incentive
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 1:29 AM EDT
Terminated Phase 2 Interventional Results available

Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC

NCT04786093
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Stereotactic radiation therapy, Durvalumab
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 24, 2026, 1:29 AM EDT
Active, not recruiting Phase 4 Interventional

Angiotensin 2 for AKI After OLT

NCT04592744
View directory record Official record
Conditions
Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
Interventions
Angiotensin II, Norepinephrine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 24, 2026, 1:29 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

NCT01564563
View directory record Official record
Conditions
Acquired Bleeding Disorder, Bleeding During/Following Surgery
Interventions
standard therapy, placebo, activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
7
States / cities
Little Rock, Arkansas • Duarte, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 24, 2026, 1:29 AM EDT
Recruiting Phase 4 Interventional

Precision Pain Management - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine on Postoperative Analgesia Among Surgical Patients at Higher Risk for Persistent Postoperative Opioid Use (POU)

NCT07672015
View directory record Official record
Conditions
Opioid Consumption, Postoperative
Interventions
Suzetrigine, Standard Care (in control arm)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 24, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

NCT00813293
View directory record Official record
Conditions
Hepatocellular Cancer
Interventions
Sorafenib, radiofrequency ablation
Drug · Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 24, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC

NCT03077243
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions
Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation
Radiation · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Gainesville, Florida • Jacksonville, Florida • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 24, 2026, 1:29 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Office-based Vision Therapy for Improving Reading and Attention in Children With Convergence Insufficiency

NCT02207517
View directory record Official record
Conditions
Convergence Insufficiency
Interventions
Office-based vergence/accommodative therapy
Procedure
Lead sponsor
Salus University
Other
Eligibility
9 Years to 13 Years
Enrollment
311 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
8
States / cities
Birmingham, Alabama • Fullerton, California • Fort Lauderdale, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 24, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

NCT00463385
View directory record Official record
Conditions
Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, Myelofibrosis
Interventions
Pomalidomide, Prednisone, Placebo to pomalidomide, Placebo to prednisone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
6
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 24, 2026, 1:29 AM EDT
Not listed Phase 2 Interventional

Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)

NCT01265576
View directory record Official record
Conditions
HCC
Interventions
Sorafenib, VT-122 (propranolol plus etodolac), Placebo
Drug
Lead sponsor
Vicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
10
States / cities
Berkeley, California • Atlanta, Georgia • New Brunswick, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 24, 2026, 1:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

VDOT for Monitoring Adherence to LTBI Treatment

NCT02641106
View directory record Official record
Conditions
Tuberculosis, Latent Tuberculosis Infection
Interventions
Video Directly Observed Therapy, In-Person DOT
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
13 Years and older
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 24, 2026, 1:29 AM EDT
Not listed Not applicable Interventional

Decentralized Dietary UC Pilot Trial

NCT02357537
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Combined Anti-inflammatory Diet (CAID)
Behavioral
Lead sponsor
Transparency Life Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 24, 2026, 1:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

NCT02325050
View directory record Official record
Conditions
Healthy
Interventions
MVA-BN-Filo, Ad26. ZEBOV, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 24, 2026, 1:29 AM EDT
Completed Not applicable Interventional

Repetitive Transcranial Magnetic Stimulation to Reduce Heroin Cravings

NCT05074524
View directory record Official record
Conditions
Opioid-use Disorder, Heroin Abuse, Craving, Transcranial Magnetic Stimulation
Interventions
Repetitive Transcranial Magnetic Stimulation, Sham Repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 64 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 24, 2026, 1:29 AM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT05091424
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions
Mosunetuzumab, Tocilizumab, Venetoclax, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
5
States / cities
Rochester, Minnesota • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 24, 2026, 1:29 AM EDT